ArticleHemaSphere2021

Adjunctive Volasertib in Patients With Acute Myeloid Leukemia not Eligible for Standard Induction Therapy: A Randomized, Phase 3 Trial.

Hartmut Döhner et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.